Kyverna Therapeutics, Inc.'s market cap is currently ―. The company's EPS TTM is $; its P/E ratio is ―; Kyverna Therapeutics, Inc. is scheduled to report earnings on March 26, 2024, and the estimated EPS forecast is $-0.70. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Sep 23	Dec 22	Dec 21
Income Statement	-
Total Revenue	-	-	-	-
Gross Profit	-	-	-	-
EBIT	-	-	-	-
EBITDA	-	-	-	-
Net Income Common Stockholders	$ -20.67M	-	-	-
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 57.54M	$ 77.27M	$ 0.00	$ 0.00
Total Assets	$ 75.19M	$ 92.49M	-	-
Total Debt	$ 9.08M	$ 9.64M	$ 0.00	$ 0.00
Net Debt	$ -48.46M	$ -67.63M	$ 0.00	$ 0.00
Total Liabilities	$ 26.02M	$ 23.72M	-	-
Stockholders Equity	$ -131.40M	$ 68.77M	$ 0.00	$ 0.00
Cash Flow	-
Free Cash Flow	$ -18.90M	-	-	-
Operating Cash Flow	$ -18.56M	-	-	-
Investing Cash Flow	$ 31.68M	-	-	-
Financing Cash Flow	$ -1.43M	-	-	-

Currency in USD

Kyverna Therapeutics, Inc. Earnings and Revenue History

Income Statement >

Kyverna Therapeutics, Inc. Debt to Assets

Balance Sheet >

Kyverna Therapeutics, Inc. Cash Flow

Cash Flow >

Kyverna Therapeutics, Inc. Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing